Azithromycin ineffective for secondary coronary heart disease prevention

For now, a 3-month regimen of azithromycin should not be used to prevent recurrent coronary heart disease (CHD) events in patients with a previous myocardial infarction and evidence of exposure to Chlamydia pneumoniae. This does not exclude the possibility that other antibiotic regimens may produce a significant benefit in reducing morbidity and mortality from CHD.

For now, a 3-month regimen of azithromycin should not be used to prevent recurrent coronary heart disease (CHD) events in patients with a previous myocardial infarction and evidence of exposure to Chlamydia pneumoniae. This does not exclude the possibility that other antibiotic regimens may produce a significant benefit in reducing morbidity and mortality from CHD.

For now, a 3-month regimen of azithromycin should not be used to prevent recurrent coronary heart disease (CHD) events in patients with a previous myocardial infarction and evidence of exposure to Chlamydia pneumoniae. This does not exclude the possibility that other antibiotic regimens may produce a significant benefit in reducing morbidity and mortality from CHD.